Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by mollevi
Last modified by jacques.colinge
Group name EquipeJC
Item Type Journal Article
Title NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation
Creator Licciardello et al.
Author M. P. Licciardello
Author M. K. Mullner
Author G. Durnberger
Author C. Kerzendorfer
Author B. Boidol
Author C. Trefzer
Author S. Sdelci
Author T. Berg
Author T. Penz
Author M. Schuster
Author C. Bock
Author R. Kralovics
Author G. Superti-Furga
Author J. Colinge
Author S. M. Nijman
Author S. Kubicek
Abstract Breast cancer is genetically heterogeneous, and recent studies have underlined a prominent contribution of epigenetics to the development of this disease. To uncover new synthetic lethalities with known breast cancer oncogenes, we screened an epigenome-focused short hairpin RNA library on a panel of engineered breast epithelial cell lines. Here we report a selective interaction between the NOTCH1 signaling pathway and the SUMOylation cascade. Knockdown of the E2-conjugating enzyme UBC9 (UBE2I) as well as inhibition of the E1-activating complex SAE1/UBA2 using ginkgolic acid impairs the growth of NOTCH1-activated breast epithelial cells. We show that upon inhibition of SUMOylation NOTCH1-activated cells proceed slower through the cell cycle and ultimately enter apoptosis. Mechanistically, activation of NOTCH1 signaling depletes the pool of unconjugated small ubiquitin-like modifier 1 (SUMO1) and SUMO2/3 leading to increased sensitivity to perturbation of the SUMOylation cascade. Depletion of unconjugated SUMO correlates with sensitivity to inhibition of SUMOylation also in patient-derived breast cancer cell lines with constitutive NOTCH pathway activation. Our investigation suggests that SUMOylation cascade inhibitors should be further explored as targeted treatment for NOTCH-driven breast cancer.
Publication Oncogene
Volume 34
Pages 3780-90
Date Jul 2015
Journal Abbr Oncogene
DOI 10.1038/onc.2014.319
ISSN 1476-5594 (Electronic) 0950-9232 (Linking)
Tags *Gene Expression Regulation, Neoplastic, *Transcriptional Activation, Apoptosis/drug effects/genetics, Blotting, Western, Breast Neoplasms/genetics/metabolism/pathology, Cell Cycle/drug effects/genetics, Cell Line, Cell Line, Tumor, Cell Proliferation/drug effects/genetics, Coculture Techniques, Flow Cytometry, Humans, Microscopy, Fluorescence, original, Receptor, Notch1/*genetics/metabolism, Reverse Transcriptase Polymerase Chain Reaction, RNA Interference, Salicylates/pharmacology, Signal Transduction/drug effects/*genetics, Small Ubiquitin-Related Modifier Proteins/genetics/metabolism, SUMO-1 Protein/genetics/metabolism, Sumoylation/drug effects/genetics, Ubiquitin-Activating Enzymes/genetics/metabolism, Ubiquitin-Conjugating Enzymes/genetics/metabolism, Ubiquitins/genetics/metabolism
Date Added 2018/11/14 - 11:48:35
Date Modified 2019/05/14 - 20:59:11
Notes and Attachments (Note)
(Note)
25263445 (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés